Cargando…

Exceptional Response to Pembrolizumab for Treatment of Metastatic Chemorefractory Endometrial Carcinoma in a Patient with Lynch Syndrome: A Case Report

Advanced endometrial cancer is associated with poor outcomes and few treatment options exist. Recently, the US Federal Drug Administration approved pembrolizumab for the treatment of endometrial cancers that are deficient in mismatch repair and have high microsatellite instability (MSI). Lynch syndr...

Descripción completa

Detalles Bibliográficos
Autores principales: Batman, Samantha, Rauh-Hain, J. Alejandro, Grinsfelder, Michaela Onstad, Harrison, Ross, Avila, Monica, Cun, Han, How, Jeffrey Andrew, Tandon, Nidhi, Wang, Xiaohong, Hinchcliff, Emily, Jazaeri, Amir Anthony, Schmeler, Kathleen M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134052/
https://www.ncbi.nlm.nih.gov/pubmed/37123608
http://dx.doi.org/10.1159/000530154
_version_ 1785031676460531712
author Batman, Samantha
Rauh-Hain, J. Alejandro
Grinsfelder, Michaela Onstad
Harrison, Ross
Avila, Monica
Cun, Han
How, Jeffrey Andrew
Tandon, Nidhi
Wang, Xiaohong
Hinchcliff, Emily
Jazaeri, Amir Anthony
Schmeler, Kathleen M.
author_facet Batman, Samantha
Rauh-Hain, J. Alejandro
Grinsfelder, Michaela Onstad
Harrison, Ross
Avila, Monica
Cun, Han
How, Jeffrey Andrew
Tandon, Nidhi
Wang, Xiaohong
Hinchcliff, Emily
Jazaeri, Amir Anthony
Schmeler, Kathleen M.
author_sort Batman, Samantha
collection PubMed
description Advanced endometrial cancer is associated with poor outcomes and few treatment options exist. Recently, the US Federal Drug Administration approved pembrolizumab for the treatment of endometrial cancers that are deficient in mismatch repair and have high microsatellite instability (MSI). Lynch syndrome is an autosomal dominant disease that causes MSI-high endometrial cancer. We report a case of a 46-year-old woman with Lynch syndrome and advanced endometrial cancer who experienced progressive disease after treatment with chemotherapy with carboplatin and paclitaxel. She was then treated with single-agent pembrolizumab and had an exceptional response. She was noted to have a significant decrease in the size of a large uterine mass extending into the vagina and vulva, as well as decrease in the size of lymphadenopathy. Data are limited at this time for patients with Lynch syndrome treated with single-agent pembrolizumab. Our case report seeks to add to the body of literature that suggests that this patient population may particularly benefit from this novel therapy.
format Online
Article
Text
id pubmed-10134052
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-101340522023-04-28 Exceptional Response to Pembrolizumab for Treatment of Metastatic Chemorefractory Endometrial Carcinoma in a Patient with Lynch Syndrome: A Case Report Batman, Samantha Rauh-Hain, J. Alejandro Grinsfelder, Michaela Onstad Harrison, Ross Avila, Monica Cun, Han How, Jeffrey Andrew Tandon, Nidhi Wang, Xiaohong Hinchcliff, Emily Jazaeri, Amir Anthony Schmeler, Kathleen M. Case Rep Oncol Case Report Advanced endometrial cancer is associated with poor outcomes and few treatment options exist. Recently, the US Federal Drug Administration approved pembrolizumab for the treatment of endometrial cancers that are deficient in mismatch repair and have high microsatellite instability (MSI). Lynch syndrome is an autosomal dominant disease that causes MSI-high endometrial cancer. We report a case of a 46-year-old woman with Lynch syndrome and advanced endometrial cancer who experienced progressive disease after treatment with chemotherapy with carboplatin and paclitaxel. She was then treated with single-agent pembrolizumab and had an exceptional response. She was noted to have a significant decrease in the size of a large uterine mass extending into the vagina and vulva, as well as decrease in the size of lymphadenopathy. Data are limited at this time for patients with Lynch syndrome treated with single-agent pembrolizumab. Our case report seeks to add to the body of literature that suggests that this patient population may particularly benefit from this novel therapy. S. Karger AG 2023-04-27 /pmc/articles/PMC10134052/ /pubmed/37123608 http://dx.doi.org/10.1159/000530154 Text en © 2023 The Author(s). Published by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Case Report
Batman, Samantha
Rauh-Hain, J. Alejandro
Grinsfelder, Michaela Onstad
Harrison, Ross
Avila, Monica
Cun, Han
How, Jeffrey Andrew
Tandon, Nidhi
Wang, Xiaohong
Hinchcliff, Emily
Jazaeri, Amir Anthony
Schmeler, Kathleen M.
Exceptional Response to Pembrolizumab for Treatment of Metastatic Chemorefractory Endometrial Carcinoma in a Patient with Lynch Syndrome: A Case Report
title Exceptional Response to Pembrolizumab for Treatment of Metastatic Chemorefractory Endometrial Carcinoma in a Patient with Lynch Syndrome: A Case Report
title_full Exceptional Response to Pembrolizumab for Treatment of Metastatic Chemorefractory Endometrial Carcinoma in a Patient with Lynch Syndrome: A Case Report
title_fullStr Exceptional Response to Pembrolizumab for Treatment of Metastatic Chemorefractory Endometrial Carcinoma in a Patient with Lynch Syndrome: A Case Report
title_full_unstemmed Exceptional Response to Pembrolizumab for Treatment of Metastatic Chemorefractory Endometrial Carcinoma in a Patient with Lynch Syndrome: A Case Report
title_short Exceptional Response to Pembrolizumab for Treatment of Metastatic Chemorefractory Endometrial Carcinoma in a Patient with Lynch Syndrome: A Case Report
title_sort exceptional response to pembrolizumab for treatment of metastatic chemorefractory endometrial carcinoma in a patient with lynch syndrome: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134052/
https://www.ncbi.nlm.nih.gov/pubmed/37123608
http://dx.doi.org/10.1159/000530154
work_keys_str_mv AT batmansamantha exceptionalresponsetopembrolizumabfortreatmentofmetastaticchemorefractoryendometrialcarcinomainapatientwithlynchsyndromeacasereport
AT rauhhainjalejandro exceptionalresponsetopembrolizumabfortreatmentofmetastaticchemorefractoryendometrialcarcinomainapatientwithlynchsyndromeacasereport
AT grinsfeldermichaelaonstad exceptionalresponsetopembrolizumabfortreatmentofmetastaticchemorefractoryendometrialcarcinomainapatientwithlynchsyndromeacasereport
AT harrisonross exceptionalresponsetopembrolizumabfortreatmentofmetastaticchemorefractoryendometrialcarcinomainapatientwithlynchsyndromeacasereport
AT avilamonica exceptionalresponsetopembrolizumabfortreatmentofmetastaticchemorefractoryendometrialcarcinomainapatientwithlynchsyndromeacasereport
AT cunhan exceptionalresponsetopembrolizumabfortreatmentofmetastaticchemorefractoryendometrialcarcinomainapatientwithlynchsyndromeacasereport
AT howjeffreyandrew exceptionalresponsetopembrolizumabfortreatmentofmetastaticchemorefractoryendometrialcarcinomainapatientwithlynchsyndromeacasereport
AT tandonnidhi exceptionalresponsetopembrolizumabfortreatmentofmetastaticchemorefractoryendometrialcarcinomainapatientwithlynchsyndromeacasereport
AT wangxiaohong exceptionalresponsetopembrolizumabfortreatmentofmetastaticchemorefractoryendometrialcarcinomainapatientwithlynchsyndromeacasereport
AT hinchcliffemily exceptionalresponsetopembrolizumabfortreatmentofmetastaticchemorefractoryendometrialcarcinomainapatientwithlynchsyndromeacasereport
AT jazaeriamiranthony exceptionalresponsetopembrolizumabfortreatmentofmetastaticchemorefractoryendometrialcarcinomainapatientwithlynchsyndromeacasereport
AT schmelerkathleenm exceptionalresponsetopembrolizumabfortreatmentofmetastaticchemorefractoryendometrialcarcinomainapatientwithlynchsyndromeacasereport